Tumor Microenvironment-Driven Immunotherapy Resistance in Solid Cancers: Emerging Biomarkers and Precision Combination Strategies

Tumor microenvironment; immunotherapy resistance; immune checkpoint blockade; precision oncology; biomarkers; metabolic reprogramming; stromal remodeling; combination therapy; immune exclusion; solid tumors.

Ataeva Muiba Sayfievna1
1
Samarkand State Medical University, Senior
teachers at the department N 1 of Pediatrics and
neonatology,
Samarkand,
Uzbekistan
https://orcid.org/0000-0003-4089-7708
[email protected]
Sarkisova Lyalya Valerevna2
2
DSc, Associate Professor of the Bukhara State
Medical Institute named after Abu Ali Ibn Sina.
[email protected]
Kamalova Gulnara Gulyamovna3
4
Associate professor, PhD. Namangan branch of
Tashkent International University of Kimyo
Mail:[email protected]://orcid.org/0009
000501315260

Received-21-05-2026
Revised-22-06-2026
Accepted-27-06-2026

European Journal of Prosthodontics and Restorative Dentistry (2026) 34(4S), 156–170

Tumor MicroenvironmentDriven
Immunotherapy
Resistance in Solid Cancers:
Emerging Biomarkers and
Precision
Combination
Strategies

The advent of immune checkpoint blockade (ICB) and other immune-based therapies has redefined cancer treatment, yielding unprecedented and durable responses in select patient subsets. However, the majority of individuals with solid malignancies either fail to respond or eventually develop resistance, highlighting a fundamental limitation in current immunotherapeutic approaches. Increasing evidence implicates the tumor microenvironment (TME) as a central orchestrator of this resistance, functioning as a complex and adaptive ecosystem that actively suppresses antitumor immunity. Immunosuppressive cell populations such as tumorassociated macrophages, myeloid-derived suppressor cells, and regulatory T cells, alongside stromal remodeling, aberrant angiogenesis, and metabolic competition, collectively restrict effective immune cell infiltration and effector function. Traditional biomarkers—such as PD-L1 expression, tumor mutational burden, and microsatellite instability—capture only fragments of this dynamic interplay and are inadequate predictors of therapeutic outcome. Advances in multi-omic profiling, spatial transcriptomics, and single-cell analytics are enabling the identification of more refined TME-related biomarkers that integrate immunologic, metabolic, and stromal signatures. These evolving frameworks hold promise for more accurate classification of resistant phenotypes and for guiding individualized therapeutic interventions. Concurrently, rationally designed combination approaches are emerging to overcome TME-mediated resistance. Strategies coupling checkpoint inhibitors with metabolic modulators, anti-angiogenic agents, oncolytic viruses, or epigenetic reprogrammers are demonstrating the ability to convert immune-excluded tumors into immune-reactive phenotypes. The future of immuno-oncology lies in precision frameworks that integrate multidimensional biomarker data with adaptive therapeutic regimens to counteract the evolving suppressive TME. Achieving this integration may redefine immunotherapy from a population-based intervention to a contextspecific, dynamically guided precision strategy capable of realizing durable remission across solid tumors.

Over the past decade, the emergence of immunotherapy has revolutionized the therapeutic paradigm of oncology, transforming once-fatal malignancies into diseases amenable to long-term immune-mediated control. The development of immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, and CTLA-4 represented a breakthrough achievement, yielding durable responses in subsets of patients with melanoma, lung cancer, renal cell carcinoma, and other solid malignancies. This shift from cytotoxic •••••••••••••••••••••••••••••••• ejprd.org- Published by Riset Publishing Services LLC.

EJPRD

Copyright © 2026 by Riset Publishing Services LLC